CLASStime: Managing headache disorders

In print

CLASStime: Managing headache disorders

By John Mottershead

In this article, John Mottershead describes some of the common and not-so-common primary and secondary headache disorders. He also provides up-to-date information on headache treatment and prevention, including non-pharmacological approaches and new treatments on the horizon

Our suite of CLASS activities provides meaningful independent and peer group learning that you can put into action, while helping you complete your an

1. GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018;17(11):954–76.

2. Thomson AN, White GE, West R. The prevalence of bad headaches including migraine in a multiethnic community. N Z Med J 1993;106(967):477–80.

3. International Headache Society. International Classification of Headache Disorders, 3rd edition. 2018.

4. Charles A. The evolution of a migraine attack - a review of recent evidence. Headache 2013;53(2):413–19.

5. Ashina M, Terwindt GM, Al-Karagholi MA, et al. Migraine: disease characterisation, biomarkers, and precision medicine. Lancet 2021;397(10283):1496–504.

6. Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78(17):1337–45.

7. Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010;50(6):921–36.

8. Wakerley BR. Medication-overuse headache. Pract Neurol 2019;19(5):399–403.

9. Raffaelli B, Neeb L, Reuter U. Monoclonal antibodies for the prevention of migraine. Expert Opin Biol Ther 2019;19(12):1307–17.